International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants (OBSTINATE)

Stéphane Zuily

Status: Enrolling

Conditions: Anticoagulants Causing Adverse Effects in Therapeutic Use; Antiphospholipid Syndrome; Thrombosis

Treatments: Drug: Rivaroxaban

Study type: Observational

Funder types: Other

Identifiers

NCT04262492

2019-A01415-52

Details and patient eligibility

About

This registry, currently being established will ensure consistency of data collection and provide safety information in non high-risk APS patients currently on DOACs.

Enrollment: 500 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient receiving a comprehensive information about the study, and not opposed to participate
• Age ≥ 18 yo
• Classification of definite APS according to revised Sapporo-Sydney criteria
• Direct oral anticoagulant treatment prescribed during at least 6 months or with the possibility of follow-up of at least 6 months

Exclusion criteria

• Incomplete revised Sapporo-Sydney criteria
• No data regarding the recurrent thrombosis
• Pregnant woman
• Age < 18 yo